Barclays Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $145.00

Gilead Sciences (NASDAQ:GILD) had its price objective decreased by Barclays from $155.00 to $145.00 in a research report report published on Wednesday morning,Benzinga reports. Barclays currently has an equal weight rating on the biopharmaceutical company’s stock.

Several other research analysts have also commented on GILD. Royal Bank Of Canada reduced their price target on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 20th. HSBC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Morgan Stanley reduced their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research note on Monday, July 27th. Finally, Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $157.93.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $130.21 on Wednesday. Gilead Sciences has a one year low of $108.46 and a one year high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The stock has a market cap of $161.66 billion, a PE ratio of 17.74 and a beta of 0.32. The stock has a 50 day moving average price of $129.61 and a 200 day moving average price of $135.87.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts expect that Gilead Sciences will post -0.78 EPS for the current fiscal year.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the transaction, the chief executive officer owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This trade represents a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 67,000 shares of company stock valued at $8,687,140. 0.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Gilead Sciences

Hedge funds have recently modified their holdings of the stock. Wealth Advisory Solutions LLC boosted its holdings in Gilead Sciences by 34.3% in the second quarter. Wealth Advisory Solutions LLC now owns 2,117 shares of the biopharmaceutical company’s stock valued at $267,000 after purchasing an additional 541 shares during the period. Bogart Wealth LLC increased its holdings in Gilead Sciences by 4.0% during the 2nd quarter. Bogart Wealth LLC now owns 70,149 shares of the biopharmaceutical company’s stock worth $8,863,000 after purchasing an additional 2,720 shares during the period. Brookmont Capital Management increased its holdings in Gilead Sciences by 0.4% during the 2nd quarter. Brookmont Capital Management now owns 37,837 shares of the biopharmaceutical company’s stock worth $4,780,000 after purchasing an additional 140 shares during the period. Flynn Zito Capital Management LLC raised its position in Gilead Sciences by 9.2% in the 2nd quarter. Flynn Zito Capital Management LLC now owns 1,881 shares of the biopharmaceutical company’s stock valued at $238,000 after purchasing an additional 158 shares in the last quarter. Finally, Pine Valley Investments Ltd Liability Co raised its position in Gilead Sciences by 7.5% in the 2nd quarter. Pine Valley Investments Ltd Liability Co now owns 2,610 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 183 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: European regulators issued a positive opinion supporting expanded use of Gilead’s Trodelvy with Keytruda for certain patients with advanced triple-negative breast cancer. The potential label expansion could broaden Trodelvy’s commercial opportunity and strengthen Gilead’s oncology pipeline. Gilead Sciences Following Trodelvy Progress and a Fair Value Debate
• Positive Sentiment: Several analyses remain favorable on GILD. One investment article argues that investors should “buy the distortion” ahead of second-quarter results, while another says the stock still appears inexpensive after delivering roughly 130% total return over five years. Gilead: Buy the Distortion Before Q2 Clears It Up Gilead Stock Stays Cheap on Its Five-Year Run
• Neutral Sentiment: Investor attention is focused on Gilead’s second-quarter 2026 results. Preview articles highlight Wall Street expectations for revenue, earnings and operating metrics, but they do not provide a confirmed earnings surprise. Wall Street Projections for Gilead’s Q2 Metrics
• Positive Sentiment: Analyst coverage remains broadly supportive, with reports noting Gilead’s market outperformance and bullish views on its prospects. However, heightened investor attention alone is not a fundamental catalyst. Do Wall Street Analysts Like Gilead Sciences Stock?
• Negative Sentiment: Erste Group Bank reduced its fiscal 2027 earnings-per-share estimate for Gilead, raising concerns about the company’s future earnings growth. Erste Group Bank Cuts Gilead FY2027 EPS Estimate
• Negative Sentiment: Barclays lowered its Gilead price target to $145. Although the revised target remains above the stock’s referenced trading level, the reduction signals more limited near-term upside and is likely weighing on sentiment. Barclays Lowers Gilead Price Target

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.